ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "quality of life"

  • Abstract Number: 2955 • 2017 ACR/ARHP Annual Meeting

    Does Guideline-Based Care Improve Outcomes That Matter to Patients? Tighter Control, Less Suffering, and Greater Well-Being over the Past Decade in Canadian RA Patients

    Susan J. Bartlett1,2, Orit Schieir3, Marie-France Valois4, Carol A Hitchon5, Janet E. Pope6, Gilles Boire7, Boulos Haraoui8, Edward C. Keystone9, Diane Tin10, Carter Thorne11 and Vivian P. Bykerk12, 1Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 4McGill University, Montreal, QC, Canada, 5University of Manitoba, Winnipeg, MB, Canada, 6Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 7Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 8Institute de Rheumatologie, Montreal, QC, Canada, 9University of Toronto, Toronto, ON, Canada, 10The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 11University of Toronto, Newmarket, ON, Canada, 122-005, Mt Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: Best practice recommendations can increase quality of care and improve clinical outcomes, however the impact of recommendations on outcomes that matter most to patients…
  • Abstract Number: 110 • 2017 Pediatric Rheumatology Symposium

    Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases

    Elina Liu1, Anastasia Dropol2, Marinka Twilt2, Pascal Tyrrell3, Shehla Sheikh4, Susanne Benseler2 and The BrainWorks Investigator Network, 1Pediatric Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada, 2Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 3Medical Imaging, University of Toronto, Toronto, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Inflammatory Brain diseases (IBrainD) are increasingly recognized causes of devastating neurological deficits in previously healthy children. Although the mortality has dramatically improved, disease and…
  • Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting

    Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey

    Ara Dikranian1, James Galloway2, Joern Kekow3, Cristiano A.F Zerbini4, Maria de la Vega5, Gavin Lee6, Anna Maniccia7, Eustratios Bananis8, Dario Ponce de Leon9 and Allan Gibofsky10, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2King's College, and King´s College Hospital, London, United Kingdom, 3University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, 4Centro Paulista de Investigação Clinica, São Paulo, Brazil, 5CEIM Investigaciones Médicas, Buenos Aires, Argentina, 6Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Collegeville, PA, 9Pfizer Inc, Lima, Peru, 10Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY

    Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…
  • Abstract Number: 890 • 2016 ACR/ARHP Annual Meeting

    Health-Related Domains of Importance to Patients with Takayasu’s Arteritis

    Antoine G. Sreih1, Fatma Alibaz-Oner2, Ebony Easley3, Trocon Davis3, Gonca Mumcu4, Nataliya Milman5, Joanna C. Robson6, Peter F. Cronholm3, Haner Direskeneli7 and Peter A. Merkel8, 1Rheumatology, The University of Pennsylvania, Philadelphia, PA, 2Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Family Medicine and Community Health, The University of Pennsylvania, Philadelphia, PA, 4Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 5Department of Medicine, University of Ottawa, Ottawa, ON, Canada, 6Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, 7Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 8Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA

    Background/Purpose: The need to include patients’ perspectives as key outcomes in clinical research is now widely recognized. This project was designed to describe the experience…
  • Abstract Number: 1433 • 2016 ACR/ARHP Annual Meeting

    Self-Perception Reporting to Healthcare Professionals: Do Individuals with Systemic Sclerosis Report Quality of Life Changes Accurately?

    Samina Hayat1, Paula Fenter2 and TIMOTHY GILMORE3, 1Rheumatology/Internal Medicine, Louisiana State University, Shreveport, LA, 2PT School of Allied Health, Louisiana St Univ Hlth Sci Ctr, Shreveport, LA, 3Program in Cardiopulmonary Science, Cardiopulmmonary Assitant Professor, Shreveport, LA

    Background/Purpose: Systemic Sclerosis (SS) involves multiple systems that affect the ability to move and function. When ability is lost the individuals living with this autoimmune…
  • Abstract Number: 1762 • 2016 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus and the Evaluation of Poor Sleep

    Philip Chu1, Alicia Hinze2, Nancy Mathis3, Lacey Feigl4, Noor Al-Hammadi5, Seth Eisen6, Yo-El Ju7 and Alfred Kim8, 1Internal Medicine, Washington University School of Medicine, St Louis, MO, 2Johns Hopkins University, Baltimore, MD, 3Rheumatology, Washington University School of Medicine, Saint Louis, MO, 4Washington University School of Medicine, St Louis, MO, 5Division of Biostatistics, Washington University School of Medicine, St Louis, MO, 6Division of Rheumatology, Washington University School of Medicine, St Louis, MO, 7Neurology, Washington University School of Medicine, Saint Louis, MO, 8IM/Div of Rheumatology, Washington University School of Medicine, St. Louis, MO

    Background/Purpose:  Poor sleep quality is an underappreciated complaint commonly observed in patients with SLE. We hypothesize that poor sleep quality contributes to worsening lupus disease…
  • Abstract Number: 1969 • 2016 ACR/ARHP Annual Meeting

    Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention

    Edith M. Williams1, Leonard Egede2, Jim Oates3, Delia Voronca2 and Mulugeta Gebregziabher2, 1Public Health Sciences, Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, SC, 3Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is associated with increased morbidity, mortality, health care costs and decreased quality of life.…
  • Abstract Number: 2192 • 2016 ACR/ARHP Annual Meeting

    Association Between Quality of Sleep and Quality of Life Among Japanese Systemic Lupus Erythematosus Outpatients

    Mitsuyo Inoue1, Kiyoko Makimoto1, Kazuko Shiozawa2, Ryosuke Yoshihara2, Takashi Yamane3, Yoshihito Shima4 and Toru Hirano5, 1Graduate School of Medicine, Division of Health Sciences, Osaka University, Suita, Japan, 2Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan, 3Kakogawa City Hospital, Kakogawa, Japan, 4Respinatory Medicine, Allergy and Rhematic Diseases, Osaka University Graduate School of Medicine, Suita, Japan, 5Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan

    Background/Purpose:  SLE outpatients at in Western Japan were included in this cross-sectional study. The consented participants completed Japanese versions of the following questionnaires: the Pittsburgh…
  • Abstract Number: 2458 • 2016 ACR/ARHP Annual Meeting

    Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review

    Omid Zahedi Niaki1, Christian A. Pineau2, Sasha Bernatsky3,4 and Evelyne Vinet3, 1Université de Montréal, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Given the obvious female predominance of rheumatic diseases, significant attention has already been drawn to the impact of these conditions on female sexual function.…
  • Abstract Number: 2515 • 2016 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA)

    Vibeke Strand1, Kathy Lampl2, Christine Birchwood3, Jinglan Pei2, Katie Tuckwell4, Rebecca Finch4, Cem Gabay5, Arthur Kavanaugh6 and Graeme Jones7, 1Stanford University School of Medicine, Palo Alto, CA, 2Genentech, Inc., South San Francisco, CA, 31 DNA Way, MS# 304, Genentech, Inc., South San Francisco, CA, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Rheumatology, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland, 6University of California San Diego, La Jolla, CA, 7Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

    Background/Purpose: Patient-reported outcomes (PROs) are important measures when determining response to therapy in patients with RA. Previous RCTs have shown that TCZ monotherapy is superior…
  • Abstract Number: 2911 • 2016 ACR/ARHP Annual Meeting

    A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients

    Carolyn Fridley1 and Virginia D. Steen2, 1Rheumatology, Georgetown University, Washington, DC, 2Rheumatology, Georgetown University Medical Center, Washington, DC

    A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease. After skin involvement…
  • Abstract Number: 717 • 2015 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study

    Alicia Hinze1, Philip Chu1, Dany Thekkemuriyil1, Yo-El Ju2, Deepali Sen3, Seth Eisen1 and Alfred Kim1, 1Rheumatology, Washington University School of Medicine, Saint Louis, MO, 2Neurology, Washington University School of Medicine, Saint Louis, MO, 3Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO

    Background/Purpose: Sleep disturbances occur in many autoimmune diseases and are ranked highly as an unmet need in patients with SLE. We hypothesized that poor sleep…
  • Abstract Number: 790 • 2015 ACR/ARHP Annual Meeting

    An Intervention to Improve Quality of Life for African-American Lupus Patients

    Edith M. Williams1, Johnese Bostic2, Alyssa Adkins3, Larisa Bruner2, Jiajia Zhang2, Diane L. Kamen4 and Jim Oates4, 1Institute for Partnerships to Eliminate Health Disparities, University of South Carolina, Columbia, SC, 2University of South Carolina, Columbia, SC, 3University of South Carolina, Greenville, SC, 4Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: The Intervention to Improve Quality of life for African-AmericaN lupus patients (IQAN) Project is designed to examine whether a uniquely tailored intervention program can…
  • Abstract Number: 2277 • 2015 ACR/ARHP Annual Meeting

    Working Harder to Stay in Control: Patient Reports of Flare in Early RA Are Associated with Higher Disease Activity and More Intensive Self Management

    Susan J. Bartlett1,2, Clifton O. Bingham III3, Daming Lin4, Kathleen Andersen5, Gilles Boire6, Carol Hitchon7, Boulos Haraoui8, Edward C. Keystone9, Diane Tin10, J Carter Thorne11, Janet E. Pope12, VP Bykerk4 and CATCH Investigators and OMERACT Flare Group, 1Clinical Epidemiology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 3Rheumatology, Johns Hopkins University, Baltimore, MD, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Hospital for Special Surgery, New York, NY, 6Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 7Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 8Institut de Rhumatologie, Montreal, QC, Canada, 9Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 10The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 11University of Toronto, Toronto, ON, Canada, 12University of Western Ontario, London, ON, Canada

    Background/Purpose: Early rheumatoid arthritis (ERA) patients attending office visits often report being in a disease flares. We evaluated patient reports of flare in relation to…
  • Abstract Number: 2313 • 2015 ACR/ARHP Annual Meeting

    Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)

    Vibeke Strand1, Regina Rendas-Baum2, George J. Joseph3, Chieh-I Chen4, Hubert van Hoogstraten5, T. W. J. Huizinga6 and Mark C. Genovese7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2QualityMetric Inc, Lincoln, RI, 3Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab is a human monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R), administered subcutaneously (SC) every 2 weeks (q2w).  In the phase…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology